Sugar Series Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions
- Product Name: Sugar Series Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions
- Factroy Site: Yudu County, Ganzhou, Jiangxi, China
- Price Inquiry: sales10@sinochem-nanjing.com
- Manufacturer: Ascent Petrochem Holdings Co., Limited
- CONTACT NOW
- Sugar Series Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is typically used in formulations when solubility and pH must be controlled within specific ranges.
| HS Code | 602879 |
| Productname | Sugar Series Veterinary Grade API |
| Productcategory | Veterinary grade active pharmaceutical ingredient/excipient |
| Productfamily | Sugar Series |
| Grade | Veterinary grade |
| Dosageforms | Tablets, Injections, Capsules, Powders, Granules, Premix, Solutions |
| Appearance | White crystalline powder, granules, or clear solution depending on form |
| Odor | Odorless |
| Taste | Sweet |
| Solubility | Freely soluble in water; slightly soluble in ethanol; practically insoluble in ether |
| Assay | ≥ 99.0% on dried basis |
| Ph | 4.5 to 6.5 for 10% w/v aqueous solution |
| Moisture | ≤ 0.5% |
| Heavymetals | ≤ 10 ppm |
| Arsenic | ≤ 2 ppm |
| Lead | ≤ 1 ppm |
| Mercury | ≤ 0.1 ppm |
| Cadmium | ≤ 0.5 ppm |
| Microbiallimits | Total aerobic count ≤ 1000 CFU/g; yeast and mold ≤ 100 CFU/g; E. coli absent |
| Endotoxin | ≤ 0.25 EU/mg for injection grade |
| Sulfatedash | ≤ 0.1% |
| Lossondrying | ≤ 0.5% |
| Chloride | ≤ 0.01% |
| Sulfate | ≤ 0.02% |
| Iron | ≤ 10 ppm |
| Particlesize | 80 to 200 mesh; customizable |
| Bulkdensity | 0.5 to 0.8 g/mL |
| Standard | Complies with USP, BP, EP, CP, or veterinary pharmacopoeial requirements |
| Application | Used in veterinary drug formulations for livestock, poultry, and companion animals |
| Targetspecies | Livestock, poultry, companion animals |
| Packaging | 25 kg net multi-wall paper bags, fiber drums, or customized packaging |
| Storage | Store in a cool, dry, well-ventilated area; protect from moisture, heat, and direct sunlight |
| Shelflife | 24 months from date of manufacture when stored properly |
| Casnumber | 50-99-7 for glucose/dextrose; varies by specific sugar type |
| Molecularformula | C6H12O6 for glucose/dextrose; varies by specific sugar type |
| Hs Code | 29400000 |
| Regulatorystatus | Veterinary API |
As an accredited Sugar Series Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Supplied in 25 kg net polyethylene-lined fiber drums or 1 kg sealed foil pouches; moisture-proof, batch-labeled veterinary API packaging. |
| Container Loading (20′ FCL) | Container Loading (20′ FCL): Sugar Series Veterinary Grade API for tablets, injections, capsules, powders, granules, premixes, and solutions securely loaded. |
| Shipping | Sugar Series Veterinary Grade API is shipped in sealed, moisture-resistant containers under controlled ambient conditions. Packaging complies with GMP and transport regulations. Tablets, capsules, powders, granules, premix, solutions, and injection-grade materials are labeled and handled to prevent contamination, moisture, and cross-contact. Store dry, away from light and incompatible substances. |
| Storage | Store Sugar Series Veterinary Grade API in original, tightly sealed containers in a cool, dry, well-ventilated area, protected from sunlight, moisture, and contamination. Keep away from incompatible materials, pests, and strong odors. Maintain labeled segregation and stock rotation. For injectable or solution grades, follow manufacturer temperature requirements; avoid freezing unless specified. Keep containers closed when not in use. |
| Shelf Life | Shelf life typically 24–36 months when stored sealed, dry, protected from light at controlled room temperature; confirm exact expiry per dosage form/manufacturer. |
In 25–500 mL flexible polyolefin and glass containers, dextrose monohydrate corresponding to 5.0% w/v anhydrous dextrose is dissolved in Water for Injection at 70 °C under low-shear agitation. The solution pH is adjusted with 0.1 M HCl or 0.1 M NaOH to 3.5–6.5 before terminal steam sterilization at 121 °C for 15 min, achieving an F0 value ≥8 for containers above 100 mL. Dextrose degradation in aqueous systems follows pH-dependent routes: at pH above 6.5, Maillard-type carbonyl-amine reactions generate 5-hydroxymethylfurfural, while at pH below 3.5, acid-catalyzed dehydration increases furan derivatives. Batch release therefore includes 5-hydroxymethylfurfural testing per Ph. Eur. 0177 and USP <1>, plus bacterial endotoxin control per USP <85> and particulate matter limits per USP <788>. The 5.0% w/v anhydrous dextrose formulation has an approximate osmolarity of 252 mOsm/L, making it suitable for peripheral administration in dogs, cats, cattle, and horses, whereas 10% w/v anhydrous dextrose at 505 mOsm/L is restricted to central venous access or slow drip in large animals. Production-scale equipment includes a 500 L 316L stainless steel jacketed vessel with bottom-mounted magnetic agitator, a 0.45 µm/0.22 µm polyethersulfone sterile filter train, and a depyrogenation tunnel operating at 250 °C for ≥30 min for glass containers. Terminal products include Dextrose 5% Injection USP, Dextrose 10% Injection USP, Dextrose 5% with 0.45% Sodium Chloride Injection, and Lactated Ringer's and Dextrose 5% Injection for fluid therapy and energy supplementation in veterinary medicine.
What Limits Lactose Monohydrate Loading in High-Shear Granulated Veterinary Tablets?
Because lactose monohydrate fragments under compaction stress while retaining low hygroscopicity, direct-compression and wet-granulated companion animal tablets use it as a filler-binder that avoids the bitter aftertaste of many active pharmaceutical ingredients. Addition ratios of 20–80% w/w are standard for wet granulated formulations; above 80% w/w, tablet tensile strength plateaus and friability exceeds 1.0% because the reduced ductile binder phase weakens interparticulate bonding during ejection on a rotary press. A representative 250 kg batch is granulated in a high-shear mixer with impeller speed 200–280 rpm, chopper speed 1,500–2,500 rpm, and wet massing time 3–5 min, followed by fluid-bed drying at inlet air temperature 60–70 °C until loss on drying reaches 1.5–3.0%. Magnesium stearate at 0.5–1.0% w/w is added in a diffusion mixer for 3–5 min; extending lubrication beyond 15 min can reduce tablet crushing strength by 20–40% through hydrophobic surface coating of lactose particles. Compression runs at 12–18 kN produce hardness 50–80 N and disintegration below 15 min in 0.1 M HCl at 37 °C per Ph. Eur. 2.9.1. Finished product types include 25 mg carprofen chewable tablets for dogs, 10 mg fenbendazole tablets for cats and dogs, 20 mg marbofloxacin tablets for dogs, and 250 mg metronidazole tablets for cats. Compliance for this application links to Ph. Eur. Lactose Monohydrate, USP-NF Lactose Monohydrate, ICH Q3D, 21 CFR 211, and VICH GL3 for stability testing of new veterinary drug substances and products.
Hard gelatin and hypromellose capsule filling for veterinary antibiotics and immunosuppressants relies on spray-dried lactose monohydrate as the core dry diluent. The formulation addition ratio ranges from 30% w/w to 90% w/w; below 30% w/w, cohesive actives with bulk density near 0.25 g/cm³ create segregation during encapsulation and require pre-blending with colloidal silicon dioxide at 0.5–1.0% w/w. Capsule fill masses between 125 mg and 500 mg require a powder blend relative standard deviation <5% after 10 min in a 600 L double-cone blender. The process stream includes sieving through 425 µm mesh, blending at 12 rpm for 15–20 min, and filling on a Zanasi Z-5000 or Bosch GKF 1500 at 60,000–150,000 capsules/h. Moisture is held at ≤5.0% for hard gelatin to prevent shell brittleness, and at ≤8.0% for hypromellose capsules to prevent sticking after 40 °C/75% RH stability exposure. Regulatory anchors include Ph. Eur. 2.9.36 powder flow, USP <1174> powder flow, ICH Q3D, EU 2019/6, and 21 CFR 210/211. Terminal finished dosage forms include 50 mg amoxicillin trihydrate capsules for dogs and cats, 100 mg gabapentin capsules for cats, 25 mg enrofloxacin capsules for avian species, and 10 mg ciclosporin capsules for dogs.
When 2% Medicated Premix Uniformity Must Survive 12-Ton Bulk Feed Mixing
In a horizontal ribbon mixer dedicated to medicated premix, dextrose monohydrate and sucrose act as particulate carriers because their bulk density and particle-size distribution reduce segregation when diluted into compound feed. In a typical 2% w/w tiamulin hydrogen fumarate premix, the sugar carrier fraction is 60–90% w/w, and the active is adsorbed or sprayed onto the carrier in a ribbon mixer operating at 20–30 rpm for 10–15 min. Mixing endpoint is accepted only when the coefficient of variation remains <5% across at least 10 sampling points per batch. Carrier particle size is controlled at D50 150–250 µm and residual moisture <3% w/w to prevent bridging and caking in 25 kg paper/polyethylene bags; batch-to-batch carrier bulk density variance from 0.55 g/cm³ to 0.75 g/cm³ shifts volumetric filling by up to 20%, so load-cell calibration is performed before each production campaign. The production route includes carrier pre-drying at 50–60 °C, active wet-spray application with 0.5–1.0% w/w mineral oil binder, ribbon blending, and final sifting through 800 µm mesh before packing. Compliance is anchored to EU Regulation 2019/4 on medicated feed, 21 CFR 558, EU 1831/2003 for feed additive authorization, and GMP+ BA2 for feed safety assurance. Terminal premix products include 10% w/w amoxicillin trihydrate premix, 20% w/w chlortetracycline hydrochloride premix, 2% w/w tiamulin hydrogen fumarate premix, and 5% w/w fenbendazole premix for swine, poultry, and ruminant feed mills.
During lyophilization cycle development for freeze-dried veterinary vaccines and β-lactam injectable powders, sugar matrices maintain cake rigidity and stabilize actives during storage. Mannitol is added at 2–10% w/v to create a crystalline bulking phase; its crystallization during freezing produces a mechanically robust cake with residual moisture <1.0% after secondary drying. Controlled freezing is essential because cooling rates faster than 1 °C/min can leave partially amorphous mannitol that collapses at shelf temperatures above −25 °C during primary drying. Sucrose or trehalose at 5–15% w/v is selected when the active requires an amorphous glass; the maximally frozen concentrated glass transition temperature of sucrose is −32 °C to −35 °C, so primary drying shelf temperature is held below −35 °C to avoid meltback and collapse. The production process begins with aseptic filtration through a 0.22 µm PVDF membrane, filling into 2–10 mL Type I borosilicate vials, shelf freezing at −40 °C to −50 °C for 3–5 h, then primary and secondary drying at chamber pressure 50–150 µbar for 24–72 h. Cake appearance is assessed by fracturing 1% of vials per batch, while moisture is measured by Karl Fischer titration. Compliance references include Ph. Eur. 5.1.1, USP <1207>, ICH Q1A(R2), and VICH GL3. Terminal products include freeze-dried live attenuated infectious bronchitis vaccine, freeze-dried penicillin G procaine injectable powder, freeze-dried ampicillin sodium for injection, and freeze-dried cell-free Marek's disease vaccine with sucrose-phosphate-glutamate stabilizer.
High-Brix Oral Drench Stability Hinges on Reducing Sugar Hydrolysis and Glycerol Partitioning
Anthelmintic and coccidiostat oral drenches for sheep and cattle use sucrose at 40–60% w/v as a palatable viscosity builder and water-activity reducer. At 60% w/v sucrose, water activity falls to 0.80–0.85, which supports preservative efficacy; however, acid-catalyzed inversion at pH <4.5 generates glucose-fructose syrup, changes specific rotation, and accelerates non-enzymatic browning during storage at 30 °C/65% RH. To limit hydrolysis, the aqueous phase is buffered with citric acid/sodium citrate to pH 5.0–6.0, and potassium sorbate is added at 0.1–0.2% w/v. Production scaling uses a high-shear inline mixer at 3,000 rpm to dissolve sucrose at 60–70 °C, followed by chilled recirculation to 25 °C, passage through a 50 µm in-line strainer, and filling into 1 L and 5 L HDPE drench containers. Batch records include density verification at 1.20–1.30 g/mL, viscosity at 25 °C of 80–400 mPa·s, and microbial limits per Ph. Eur. 5.1.3. Regulatory anchors include VICH GL3, EU 2019/6, and 21 CFR 210/211. Terminal products include 2.5% w/v ivermectin oral drench, 20% w/v levamisole hydrochloride oral drench, 2.5% w/v toltrazuril oral suspension, and 10% w/v albendazole oral suspension.
For neonatal calf and piglet rehydration powders, dextrose monohydrate is incorporated as the sodium–glucose co-transport substrate that drives SGLT1-mediated fluid absorption across the intestinal epithelium. A final rehydration solution containing 13.5 g/L anhydrous dextrose, 2.6 g/L sodium chloride, 2.9 g/L trisodium citrate, and 1.5 g/L potassium chloride yields an osmolarity of 245–260 mOsm/L, which is hypotonic relative to calf plasma and reduces the risk of osmotic diarrhea. In the dry blend, dextrose monohydrate is used at 20–40% w/w, with the remainder comprising sodium chloride, potassium chloride, trisodium citrate, and in some oral rehydration salts a small fraction of glycine or alanine. Production is carried out in a V-blender at 15 rpm for 10 min, with in-process moisture held below 0.5% w/w and the blend discharged through an 800 µm conical mill to remove agglomerates. Sachet filling is performed on vertical form-fill-seal equipment at 40–60 sachets/min using LDPE/aluminum foil/PET laminate to maintain water vapor transmission rate below 0.1 g/m²/day. Compliance points include the WHO/FAO revised oral rehydration salts formula, ICH Q3D, EU 2019/6, and VICH GL3. Terminal products include 20 g calf rehydration sachets, 100 g piglet electrolyte powders, 4 g dog electrolyte tablets, and 25 g sheep electrolyte powders.
Multiparticulate dosage forms for equine and companion animal oral administration use sucrose/starch non-pareil spheres at 200–355 µm or 355–500 µm as starter cores for drug layering and polymeric coating. The sugar sphere fraction is typically 60–80% w/w of the final granule, depending on drug load. In a Wurster fluid-bed coater with column diameter 150–300 mm, active suspension is sprayed at 5–10 g/min with inlet air temperature 50–60 °C, product temperature 38–42 °C, and atomization pressure 0.8–1.5 bar. After drug layering, enteric coating with methacrylic acid–ethyl acrylate copolymer is applied to achieve 20–30% weight gain, and dissolution testing is performed in 0.1 M HCl for 2 h followed by phosphate buffer pH 6.8 per Ph. Eur. 2.9.3. Compliance anchors include USP <711>, ICH Q3D, and EU 2019/6. Terminal products include omeprazole oral paste for horses containing enteric-coated sugar spheres, fenbendazole granules for dogs, and probiotic granules for cats.
Competitive Sugar Series Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618963613625 or mail to sales10@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8618963613625
Email: sales10@sinochem-nanjing.com
Get Free Quote of Ascent Petrochem Holdings Co., Limited
Flexible payment, competitive price, premium service - Inquire now!
- Sugar Series Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is manufactured under an ISO 9001 quality system and complies with relevant regulatory requirements.
- COA, SDS/MSDS, and related certificates are available upon request. For certificate requests or inquiries, contact: sales10@sinochem-nanjing.com.
Released as a veterinary-grade active pharmaceutical ingredient, the Sugar Series is a multi-grade platform that separates the active substance into formulation-specific physical forms for tablets, injections, capsules, powders, granules, premix, and solutions. Chemical identity remains consistent across the series; the differences are introduced through controlled crystallisation, milling, terminal sterilisation, and packaging. This design distinguishes it from single-grade veterinary APIs that rely on a common powder for all dosage forms. The relevant standards for release are the Ph. Eur. monographs for veterinary medicinal products, USP <711> and USP <905> for solid oral dose uniformity, Ph. Eur. 2.6.14 for bacterial endotoxins, and VICH GL18(R) for residual solvent classification. The series should be evaluated only against the grade-specific certificate of analysis; published data for this specific configuration is limited, and equivalence to non-sugar platform APIs must be demonstrated by the finished dosage manufacturer.
What physicochemical specifications distinguish the Sugar Series grades?
Seven model identifiers are assigned across the series: oral tablet grade, injectable solution grade, capsule grade, fine powder grade, granule grade, premix grade, and liquid solution grade. The oral direct-compression grade is controlled for particle size distribution by laser diffraction under ISO 13320:2020, with the D10, D50, and D90 values stated in the manufacturer’s drug master file. Bulk density and tapped density are determined according to ASTM D6393-21, and the derived Carr index is used to flag lot-to-lot variation that could affect tableting. Residual water is measured by USP <921> Karl Fischer titration, not by loss on drying alone, because bound water in sugar-based matrices can shift glass transition, and because the granulated grade requires a moisture specification that is compatible with wet massing. The injection grade is additionally released for sub-visible particulates according to USP <788> or Ph. Eur. 2.9.19, and for endotoxin under Ph. Eur. 2.6.14. The capsule and powder grades are tested for powder flow through an orifice under USP <1174>; the premix grade is sieved for coarse particle retention with USP <786>.
| Grade | Series code | Release parameters | Reference methods | Operational boundary |
|---|---|---|---|---|
| Tablet | SVT-100 | Particle size D10/D50/D90, moisture, powder flow | ISO 13320:2020, USP <921>, ASTM D6393-21 | Direct compression only after dry blending; avoid lubricant above 1.0% w/w |
| Injection | SVI-200 | Endotoxin, sub-visible particulates, bioburden | Ph. Eur. 2.6.14, USP <788>, Ph. Eur. 2.6.12 | Aseptic processing; terminal sterilisation after stability verification |
| Capsule | SVC-300 | Bulk density, flow index, particle shape | ASTM D6393-21, USP <1174> | Pre-compression if Carr index exceeds 30 |
| Powder | SVP-400 | Dissolution, moisture, residue on ignition | USP <711>, USP <921>, USP <281> | Direct reconstitution in potable water; visual dispersion before dosing |
| Granule | SVG-500 | Sieve retention, moisture, friability | USP <786>, USP <921> | Wet granulation with end-point defined by torque, not time |
| Premix | SVM-600 | Coarse sieve retention, blend uniformity, microbial limits | USP <786>, USP <905>, Ph. Eur. 2.6.12 | Stepwise blending; no single dilution step exceeding 1:100 without validation |
| Solution | SVS-700 | Clarity, pH, preservative compatibility | Ph. Eur. 2.2.1, Ph. Eur. 2.2.2 | Filtration before filling; avoid contact with uncoated silicone tubing |
Powder flow is not a single number. The direct-compression grade is evaluated with a Schulze ring shear tester under pre-shear normal stress of 9 kPa; the unconfined yield strength is calculated according to ASTM D6773-22 and used to predict arching in hoppers. A wall friction angle below 20 degrees on stainless steel is typical for smooth surfaces, but the specific value for the Sugar Series is lot-dependent. If the wall friction angle increases, mass flow from the tablet press hopper can transition to funnel flow, causing segregation. At rotary tablet press speeds above 60,000 tablets per hour, even small differences in bulk density can produce weight variation failures that are not detected until the press stops for sampling.
Solid oral dosage forms: compression, wet granulation and capsule fill parameters
Tablet and capsule utilisation depends on the compressibility profile of the direct-compression grade. Process windows are narrow because the sugar-based matrix can exhibit plastic deformation at low moisture content and brittle fracture at over-dried conditions. The granulated grade is used when higher drug loading or poor flow demands wet granulation. A solution of binder is added to the granulated material in a high-shear mixer; the end point is determined by torque or impeller power draw rather than time alone. Drying is typically performed in a fluid-bed dryer with inlet air temperature below the melting or decomposition limit of the active substance. The dried granules are milled through a cone mill or oscillating sieve to achieve the nominal particle size distribution.
For capsule filling, the powder or pellet grade should meet weight variation requirements of USP <905> at filling speeds up to the limit of the capsule machine. If flow falls below a Carr index of approximately 25 to 30 as measured by ASTM D6393-21, pre-compression or granulation is required. Tablet compression is performed using rotary presses with pre-compression stations; the specific main compression force is a function of the tooling size and the hardness target established by the finished product specification. Excess lubrication, particularly magnesium stearate above 1.0% w/w, can reduce tablet hardness and dissolution rate.
During wet massing, the sugar-based matrix can dissolve locally at the binder addition site. If impeller tip speed exceeds 6 m/s in a high-shear mixer, frictional heating may raise the wet mass temperature above the glass transition and create hard agglomerates that cannot be milled. For a 250 kg bowl, tip speeds of 3 m/s to 5 m/s are typical, but the actual value must be confirmed by torque response. Once the wet mass reaches the required end-point, immediate transfer to a fluid-bed dryer with inlet air at 40°C to 55°C is standard; higher air temperatures may cause surface crusting while the core remains wet. The outlet air temperature and the pressure drop across the filter bags are used as secondary indicators of drying rate, and the final moisture is confirmed by USP <921> Karl Fischer titration.
Because the sugar-based matrix can contain reducing sugar moieties, formulators should avoid prolonged contact with primary amines and high-pH buffers, which can initiate Maillard degradation. Compatibility studies should be performed at the target pH and temperature before combining the Sugar Series with amine-containing preservatives or coatings. Physical incompatibility with hard gelatin capsule shells may also occur if the powder-grade moisture exceeds the specification; moisture transfer to the shell can cause cross-linking or brittle fracture.
Injectable-grade material from the Sugar Series is not a milled derivative of the oral powder. It is manufactured under a separate closed process where the solution is passed through sterilising-grade filtration and aseptically filled or lyophilised. The release specifications include bacterial endotoxin action limits derived from the route of administration and target species; for parenteral products the manufacturer’s stated limit must be below the maximum permitted by Ph. Eur. 5.1.10 and USP <85>, but the lot-specific value is provided on the certificate of analysis. Terminal sterilisation of the finished injection is possible only when the active substance remains stable; otherwise aseptic compounding is required. The injectable grade is not necessarily sterile in all presentations; the certificate of analysis states whether the material is sterile or aseptically processed. In use, the injectable grade is intended for extemporaneous preparation by a licensed veterinarian or pharmacist under conditions that maintain sterility, because the API cannot correct contamination introduced during compounding.
For solutions, the Sugar Series solution grade is dissolved in purified water or a buffered vehicle before filling. The dissolution profile of the API in the vehicle is confirmed by USP <711> or the finished product monograph. If the dosage form is a powder for oral solution, the powder grade is dissolved in potable water at the point of administration; crystal size and wettability must be controlled because a very fine particle size may increase surface energy and cause aggregation at the air-liquid interface. In powders and granules intended for direct addition to drinking water, the sugar-based matrix can reduce dust generation compared with non-coated powders, but the equipment should still be designed for dust containment. For feed premix applications, low-dose inclusion below 5.0% of the active substance in feed requires stepwise mixing: the Sugar Series premix grade is first blended with a small portion of carrier, then this intermediate premix is diluted into a larger batch. Blend uniformity is evaluated by collecting stagewise samples and comparing active content against the theoretical label claim; acceptance criteria generally follow the finished product monograph and USP <905> when applicable to single-dose units, but for bulk feed premixes the manufacturer’s validation protocol defines the maximum relative standard deviation. Failure to account for electrostatic charge on the dry powder can reduce recovery from plastic blending containers; humidity control above 60% RH may be required if the grade exhibits hygroscopic behaviour.
When Sugar Series granules are dry-blended for feed premix instead of direct compression
When granules are dry-blended for feed premix rather than compressed into tablets, the granule density and particle shape must be reconsidered. Granules prepared for tableting often contain a binder and are densified to improve die filling; in feed premix, dense granules can segregate during transport because vibration moves smaller particles downward and larger or denser particles upward. To prevent segregation, the manufacturer recommends a sieve cut that matches the carrier particle size, and the granule is blended in a ribbon mixer with the carrier for a time determined by tracer study. A production-scale ribbon mixer with a working capacity of 500 kg may require three to five blending stages depending on the active substance concentration. Discharge gates should not be opened directly from the top surface; sampling must include the dead zones behind baffles and at the discharge throat. If the coefficient of variation for active content exceeds 5.0%, the batch should not be released without re-screening. Compared with direct compression granules, the premix-grade Sugar Series material is often lower in fines to reduce dust, but too few fines can impair distribution of the active substance across the carrier surface.
Residual solvent and storage stability boundaries
The Sugar Series is released for residual solvents according to VICH GL18(R); Class 1 solvents are controlled or absent, Class 2 solvents are limited to the permitted daily exposure, and Class 3 solvents are monitored to avoid accumulation in reconstituted oral solutions. Stability of the solid grades is affected by temperature, humidity, and packaging. The manufacturer stores bulk material in sealed polyethylene-lined fibre drums under controlled humidity. Once opened, the powder should be used within the shortest period permitted by the stability protocol; if the storage area exceeds the specified relative humidity, the material may require oven drying before compression. The injectable-grade solution must be stored in glass or suitable polymeric containers that do not leach plasticisers; compatibility with rubber stoppers should be tested by the finished dosage manufacturer because the active substance may interact with stopper extractables. Light-sensitive grades are shipped in amber containers; re-packaging into clear containers without photostability data is not recommended. The storage conditions and shelf life are stated on the certificate of analysis and the labelling, not in promotional summaries.
| Control area | Reference | Application to Sugar Series |
|---|---|---|
| Residual solvents | VICH GL18(R) | Class 1 solvents absent or controlled; Class 2 and Class 3 solvents monitored in each lot |
| Endotoxin release | Ph. Eur. 2.6.14, USP <85> | Applied to injectable grade; action limit set by route and species |
| Uniformity of dosage units | USP <905>, Ph. Eur. 2.9.5 | Finished tablet and capsule batches must meet acceptance values |
| Dissolution performance | USP <711>, Ph. Eur. 2.9.3 | Used for solid oral grades and reconstituted powders |
| Powder flow characterisation | ASTM D6393-21, ASTM D6773-22 | Carr index and yield strength for hopper design |
| Particle size distribution | ISO 13320:2020, USP <786> | Grade-specific D10/D50/D90 and sieve retention |
| Cleanroom manufacture | ISO 14644-1:2015 | Injectable grade processed in classified area |
| Component testing and release | 21 CFR 211.84 | Finished dosage manufacturer must test each lot |
The principal difference between the Sugar Series and other veterinary APIs is that the same active substance is not supplied as a single powder for all dosage forms. A single-grade material may be acceptable for oral tablets but may carry an excessively high endotoxin load for parenteral use or may contain fines that cause segregation in feed premix. In the Sugar Series, the injectable grade is separated from the oral grades at the point of crystallisation and is not obtained by merely sieving or blending an oral powder. This separation reduces the risk of cross-contamination in the finished dosage form and allows each grade to be released against the test methods relevant to its intended use. Other suppliers may offer only a compacted oral grade; the user must then perform micronisation or deagglomeration on site, which can alter particle size distribution and introduce metal contamination from milling. The Sugar Series also differs from sugar excipients such as compressible sucrose or mannitol because it contains the active substance; it is not a filler, binder, or coating agent. Users should not substitute one series grade for another without repeating the process validation, because particle size, bulk density, and residual water specifications are grade-specific. The manufacturer’s drug master file contains the complete release data, but the finished dosage manufacturer remains responsible for confirming that the chosen grade meets the requirements of 21 CFR 211.84 and the relevant veterinary marketing authorisation.
